Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company headquartered in Salt Lake City, Utah, with news flow centered on silicon nitride–based medical technologies, implant systems, and infection‑prevention platforms. This news page aggregates company press releases and third‑party coverage so readers can follow developments in its silicon nitride biomaterials, polymer composites, and antipathogenic fabric technologies.
Recent SINTX news highlights regulatory milestones and product launches, including U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and the launch of OsseoSculpt, a biologic designed to complement the SINAPTIC wedge portfolio. Updates also cover the company’s focused commercialization plan around infection‑resistant silicon nitride devices and polymer composites, as well as early product revenue from OsseoSculpt.
Investors and industry observers will find coverage of strategic agreements, such as the supply agreement with EVONIK to manufacture SINTX’s proprietary SiN/PEEK compound for AI‑assisted, 3D‑printed, patient‑specific implants. News items also track SINTX’s intellectual‑property progress, including Notices of Allowance from the United States Patent and Trademark Office for composition and method patents covering antipathogenic fibrous materials and fabric technologies.
In addition, SINTX issues releases on capital markets activity and corporate events, including warrant exercises, at‑the‑market offering arrangements, and participation in investor conferences hosted by firms such as H.C. Wainwright and Sidoti & Company. These updates provide context on the company’s financing strategy and investor outreach.
By monitoring this page, readers can review SINTX news related to medical device clearances, biologic product introductions, infection‑prevention patents, financing transactions, and investor presentations, all in one place.
SINTX Technologies has entered a joint development agreement with Iwatani Corporation of America to integrate SINTX AP2 silicon nitride powder into polymer materials. This collaboration aims to create antimicrobial surfaces for IT devices, potentially reducing the spread of respiratory diseases like SARS-CoV-2 and Influenza A. The development leverages promising data showing silicon nitride's effectiveness against viruses. Both companies plan to fund product development in both the U.S. and Japan. SINTX emphasizes this partnership as a significant step towards new product offerings and revenue generation.
SINTX Technologies has achieved AS9100D certification for its Quality Management System, allowing the company to supply components to the aviation, space, and defense markets. Certified by the British Standards Institute on October 28, 2020, SINTX's compliance with AS9100D enables listing in the OASIS database, used by major aerospace companies like Boeing and Lockheed Martin for supplier selection. In addition to AS9100D, SINTX maintains ISO 9001:2015 and ISO 13485:2016 certifications, underscoring its commitment to stringent quality standards across sectors.
SINTX Technologies has secured US Patent 10,806,831, which covers antibacterial biomedical implants utilizing silicon nitride. This patent expands the company's capability to enhance the antibacterial properties of various implants, including those made from PEEK and titanium. The company plans to launch a composite product in early 2021. SINTX's silicon nitride can also be used in face masks to neutralize pathogens. This patent strengthens SINTX's intellectual property position in the biomedical sector.
SINTX Technologies, Inc. (NASDAQ: SINT) has announced progress in the development of a "catch-and-kill" mask designed to inactivate respiratory viruses, including SARS-CoV-2. The company has successfully embedded silicon nitride particles into fabric, marking a significant step in mask production. The next phases involve fabric testing and manufacturing scale-up. Dr. Bal, CEO of SINTX, emphasizes the mask's potential market beyond COVID-19, addressing air quality concerns in densely populated areas. Collaboration with O2TODAY aims to bring this innovative mask to market, enhancing public health safety.
SINTX Technologies has appointed Michael Marcroft as Vice President of Business Development, focusing on the medical device sector. With nearly 20 years of experience from companies like 3M and Medtronic, Marcroft aims to leverage the potential of silicon nitride, a key biomaterial. Dr. Sonny Bal, CEO, expressed confidence that Marcroft's expertise will open new market opportunities. SINTX, specializing in silicon nitride ceramics, is positioned for growth in diverse medical applications, including arthroplasty and dental implants.
SINTX Technologies (NASDAQ: SINT) announced the filing of a universal shelf registration statement on Form S-3 with the SEC. The filing allows SINTX to access capital markets in the future up to $75 million, enhancing financial flexibility for growth opportunities. While there are no immediate plans to issue securities, this move is considered prudent for standard corporate governance. The registration statement has not yet become effective, and sales will only occur following its effectiveness.
SINTX Technologies (NASDAQ: SINT) announced new studies confirming that its silicon nitride inactivates SARS-CoV-2 and Influenza A. Conducted at George Mason University, the findings highlight a strong, dose-dependent antiviral effect after just one minute of exposure. The research aims to advance the development of consumer masks incorporating silicon nitride. SINTX is exploring additional applications in various industries, including automotive and biomedicine, while collaborating with O2TODAY on mask production. Notably, silicon nitride is non-toxic to mammalian cells.
SINTX Technologies, an OEM ceramics company specializing in silicon nitride, has announced a business update conference call on August 19th, 2020, at 3:00 p.m. Eastern Time. Interested parties can join the call by dialing 877-524-8416 or 412-902-1028 internationally. Questions for the call can be submitted via email to IR@SINTX.com until 9:00 a.m. Eastern Time on August 17. A digital replay of the call will be available on the SINTX website.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the closing of a registered direct offering of 3,415,000 shares at $2.40 per share, raising gross proceeds of $8.2 million. The shares were offered under a previously filed shelf registration statement. Maxim Group LLC served as the sole placement agent. The proceeds will be allocated for general working capital and corporate purposes. SINTX specializes in the production of silicon nitride ceramics for medical applications, with its manufacturing facility FDA registered and ISO certified.
SINTX Technologies has entered into a share purchase agreement to issue 3,415,000 shares at $2.40 each, generating approximately $8.2 million. This registered direct offering is priced at-the-market under Nasdaq rules and is expected to close on August 7, 2020, pending customary closing conditions. Maxim Group LLC is the sole placement agent for this offering, which is conducted under a previously filed Form S-3 registration statement.
The shares will be offered via a supplement to the existing prospectus filed with the SEC.